Janux Therapeutics, Inc.
JANX
$13.85
-$0.20-1.42%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -100.00% | -- | |||
| Cost of Revenue | -8.90% | 18.69% | |||
| Gross Profit | -28.09% | 15.58% | |||
| SG&A Expenses | 2.17% | 1.61% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.30% | 0.29% | |||
| Operating Income | -20.28% | 21.87% | |||
| Income Before Tax | -31.39% | 28.19% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -31.39% | 28.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -31.39% | 28.19% | |||
| EBIT | -20.28% | 21.87% | |||
| EBITDA | -20.67% | 22.05% | |||
| EPS Basic | -31.12% | 28.34% | |||
| Normalized Basic EPS | -31.14% | 28.32% | |||
| EPS Diluted | -31.12% | 28.34% | |||
| Normalized Diluted EPS | -31.14% | 28.32% | |||
| Average Basic Shares Outstanding | 0.20% | 0.20% | |||
| Average Diluted Shares Outstanding | 0.20% | 0.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||